A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies
Harvey, R D, Owonikoko, T K, Lewis, C M, Akintayo, A, Chen, Z, Tighiouart, M, Ramalingam, S S, Fanucchi, M P, Nadella, P, Rogatko, A, Shin, D M, El-Rayes, B, Khuri, F R, Kauh, J SVolume:
108
Language:
english
Journal:
British Journal of Cancer
DOI:
10.1038/bjc.2012.604
Date:
March, 2013
File:
PDF, 107 KB
english, 2013